ACR Appropriateness Criteria<sup>®</sup> Prostate Cancer-Pretreatment Detection, Surveillance, and Staging.

导出 LinkOut

翻译打印收藏纠错

作者： Expert Panel on Urologic Imaging: ^[1] ; Fergus V,Coakley ^[2] ; Aytekin,Oto ^[3] ; Lauren F,Alexander ^[4] ; Brian C,Allen ^[5] ; Brian J,Davis ^[5] ; Adam T,Froemming ^[6] ; Pat F,Fulgham ^[7] ; Keyanoosh,Hosseinzadeh ^[8] ; Christopher,Porter ^[9] ; V Anik,Sahni ^[3] ; David M,Schuster ^[10] ; Timothy N,Showalter ^[11] ; Aradhana M,Venkatesan ^[12] ; Sadhna,Verma ^[13] ; Carolyn L,Wang ^[14] ; Erick M,Remer ^[15] ; Steven C,Eberhardt

作者单位： Principal Author, Oregon Health & Science University, Portland, Oregon. Electronic address: coakleyf@ohsu.edu. ^[1] Panel Vice-Chair, University of Chicago, Chicago, Illinois. ^[2] Emory University Hospital, Atlanta, Georgia. ^[3] Duke University Medical Center, Durham, North Carolina. ^[4] Mayo Clinic, Rochester, Minnesota. ^[5] Urology Clinics of North Texas, Dallas, Texas; American Urological Association. ^[6] Wake Forest University School of Medicine, Winston Salem, North Carolina. ^[7] Virginia Mason Medical Center, Seattle, Washington; American Urological Association. ^[8] Brigham & Women's Hospital, Boston, Massachusetts. ^[9] University of Virginia, Charlottesville, Virginia. ^[10] University of Texas MD Anderson Cancer Center, Houston, Texas. ^[11] University of Cincinnati Medical Center, Cincinnati, Ohio. ^[12] University of Washington, Seattle Cancer Care Alliance, Seattle, Washington. ^[13] Specialty Chair, Cleveland Clinic, Cleveland, Ohio. ^[14] Panel Chair, University of New Mexico, Albuquerque, New Mexico. ^[15]

关键词 AUC Appropriate Use Criteria Appropriateness Criteria cancer imaging prostate staging